Lucira Health, Inc. (LHDX) News

Lucira Health, Inc. (LHDX): $5.89

0.02 (+0.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LHDX News Items

LHDX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LHDX News Highlights

  • For LHDX, its 30 day story count is now at 7.
  • Over the past 26 days, the trend for LHDX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • LAW and PTE are the most mentioned tickers in articles about LHDX.

Latest LHDX News From Around the Web

Below are the latest news stories about Lucira Health Inc that investors may wish to consider to help them evaluate LHDX as an investment opportunity.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Lucira Health, Inc. - LHDX

Pomerantz LLP is investigating claims on behalf of investors of Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Yahoo | October 16, 2021

Understanding Changes in Lucira Health’s Risk Factors

Lucira Health (LHDX) is an American medical technology company that makes test kits for infectious diseases. Its products include a COVID-19 test kit that can be purchased without a prescription and used at home. (See Analysts’ Top Stocks on TipRanks) Let’s take a look at the company’s latest financial performance, corporate updates, and changes in risk factors. Q2 Financial Results Lucira Health reported revenue of $12.4 million for Q2 2021 and beat consensus estimates of $8 million. The company did not book any revenue in the same quarter last year. It said that the sale of its COVID-19 test kits was a major revenue driver in the latest quarter.

Neha Gupta on TipRanks | October 13, 2021

At-home Covid test from East Bay company hit by swab recall

The recall is the latest hiccup in a Covid rapid-testing market already stressed by supply chain issues and test failures.

Yahoo | October 12, 2021

LUCIRA™ HEALTH COVID-19 Test Approved for Sale in Singapore

Singapore Health Sciences Authority issues approval by its Pandemic Special Access Route (PSAR) for the LUCIRA CHECK IT COVID-19 Test Kit. Lucira has partnered with Labgistics Asia Pte Ltd for the importation and distribution of its products in Singapore.EMERYVILLE, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira") (Nasdaq: LHDX), a medical technology company focusing on the development and commercialization of transformative and innovative infectious di

Yahoo | October 12, 2021

Lucira Health, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Lucira Health, Inc. ("Lucira" or the "Company") (NASDAQ: LHDX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss the

Yahoo | October 11, 2021

LUCIRA™ HEALTH Provides Statement on Copan’s Recall of its FLOQSwabs

EMERYVILLE, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today commented on the recent recall of the FLOQSwabs by supply partner Copan Italia SPA, or Copan. Copan, who supplies FLOQSwabs included in the LUCIRA COVID-19 All-In-One Test Kit and LUCIRA CHECK IT COVID-19 Test Kit, collectively the T

Yahoo | October 8, 2021

LUCIRA™ HEALTH Hires Tony Allen as Chief Operations Officer

Veteran operations expert joins Lucira’s management teamEMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced operations expert Tony Allen has joined the company as Chief Operations Officer. “Tony has a stellar track record in operations management. We’re delighted that he’s

Yahoo | September 20, 2021

LUCIRA™ HEALTH Hires Ghazi Kashmolah as Chief Quality Officer and EVP Regulatory Affairs

EMERYVILLE, Calif., August 23, 2021--Lucira Health, Inc. ("Lucira Health" or "Lucira") (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced life science professional Ghazi Kashmolah has joined the company as Chief Quality Officer and Executive Vice President Regulatory Affairs.

Yahoo | August 23, 2021

3 Beaten-Down Biotech Stocks to Buy Right Now

Volatility comes with the territory when you invest in biotech stocks. Here's why they chose Bluebird Bio (NASDAQ: BLUE), Lucira Health (NASDAQ: LHDX), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (Bluebird Bio): Shares of Bluebird Bio have been hammered in recent years.

Yahoo | August 18, 2021

Lucira Health, Inc. (LHDX) Q2 2021 Earnings Call Transcript

After the speakers' presentation, there will be a question-and-answer session [Operator instructions] I would now like to hand the conference over to your first speaker today, Hannah Jeffrey from Gilmartin Group. Earlier today, Lucira Health released financial results for the second quarter ended June 30, 2021. Joining me today on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.

Yahoo | August 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 4.1035 seconds.